The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

The results come from Part 1 of the ESSENCE trial, which involved around 800 patients treated with semaglutide or placebo on top of standard care and followed for 72 weeks. MASH is a form of non ...

Though the precise nature of these ingredients may be a mystery, having at least an idea of how much semaglutide-like substance is in each dose can help clinicians aid their patients with diet and ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient ... depending on the patient's response. In clinical trials, Victoza helped lower A1C by up to 1.5%.